Lifestyle Intervention for Rheumatoid Arthritis

Sponsor
Blue Cross Blue Shield of Vermont (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT05554705
Collaborator
(none)
200
1
2
24
8.3

Study Details

Study Description

Brief Summary

The main purpose of this study is to assess whether adding a multifaceted lifestyle intervention to the standard best practice of care can be more effective than standard best practices alone for treating Rheumatoid Arthritis.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Intensive Lifestyle intervention
N/A

Detailed Description

The main purpose of this study is to assess whether adding a multifaceted lifestyle intervention to the standard best practice of care can be more effective than standard best practices alone for treating Rheumatoid Arthritis. If a lifestyle intervention is effective, we expect to see improvement in functional status and decreased health care costs to the study participant and the insurer.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
200 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
A Lifestyle Intervention for Rheumatoid Arthritis: Effect of an Intensive Therapeutic Lifestyle Change Program on Inflammatory Markers and Clinical Outcomes
Anticipated Study Start Date :
Jan 1, 2023
Anticipated Primary Completion Date :
Jan 1, 2025
Anticipated Study Completion Date :
Jan 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: experimental

standard of care + lifestyle intervention

Behavioral: Intensive Lifestyle intervention
12 week therapeutic lifestyle change program

No Intervention: control

no intervention (control group)

Outcome Measures

Primary Outcome Measures

  1. Change in HAQ-2 score [Up to 24 months]

    The HAQ-II is a validated and reliable tool used frequently by rheumatologists evaluating patients with RA (Wolfe et al, 2004). It is an indicator of quality of life as well as functional status. It is also a predictor of premature mortality.

  2. Change in serum C-Reactive Protein [Up to 24 months]

    CRP is a reliable marker of acute and chronic inflammation (Sproston and Ashworth, 2018).

Secondary Outcome Measures

  1. Change in dosage of RA-related medications [Up to 24 months]

    Dosage of Medications Taken Specifically for Rheumatoid Arthritis

  2. Change in the number of medications required to treat RA [Up to 24 months]

    Number of Medications Taken Specifically for Rheumatoid Arthritis

  3. Change in RA-related costs for the study participant [Up to 24 months]

    Out of Pocket costs related to Rheumatoid Arthritis Care

  4. Change in RA-related costs to the insurer [Up to 24 months]

    Costs for care of Rheumatoid Arthritis paid by insurer

  5. Change in serum LDL cholesterol [Up to 24 months]

    Elevated Low Density Lipoprotein is strongly associated with heart disease

  6. Change in serum total cholesterol [Up to 24 months]

    Elevated total cholesterol is associated with heart disease

  7. Change in serum HbA1c [Up to 24 months]

    Hemoglobin HbA1c is used to assess glucose control in diabetics

  8. Change in blood pressure [Up to 24 months]

    Blood pressure change

  9. Change in BMI [Up to 24 months]

    Body Mass Index change

  10. Change in weight [Up to 24 months]

    Weight change

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. BCBSVT members who also carry the prescription benefit with BCBSVT (due to the need for tracking prescription costs).

  2. BCBSVT membership for minimum of 12 months prior to start of study (due to the need for tracking prescription costs before and after intervention).

  3. Age 18 or older

  4. Medical diagnosis of RA

Exclusion Criteria:
  1. Pregnancy

  2. Currently taking warfarin (since fluctuating amounts of green leafy vegetable intake can adversely affect INR levels and because we will be asking participants to increase the amount of green leafy vegetables they consume)

  3. Malignancy currently undergoing treatment (with further planned treatment at the time of enrollment) since patients undergoing cancer treatment often need to stop RA medications in order to improve immune function, and thus could be a confounder.

  4. Food allergy (including reactions such as hives, wheezing, difficulty breathing, fainting, or anaphylaxis)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Blue Cross Blue Shield of Vermont Berlin Vermont United States 05602

Sponsors and Collaborators

  • Blue Cross Blue Shield of Vermont

Investigators

  • Principal Investigator: Keri LeCompte, PharmD, Blue Cross Blue Shield of Vermont

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Blue Cross Blue Shield of Vermont
ClinicalTrials.gov Identifier:
NCT05554705
Other Study ID Numbers:
  • 22-08-629-1275
First Posted:
Sep 26, 2022
Last Update Posted:
Sep 26, 2022
Last Verified:
Sep 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 26, 2022